Taken as a whole, these results suggest that Flt3-L treatment during influenza infection partially protects against secondary bacterial infection as reflected by decreased bacterial counts (reduced systemic dissemination), reduced pneumonia and prolonged survival. Here, FLT3LG is linked to pneumonia.